The developer of the country’s first indigenous surgical robotic technology, SS Innovations, the visionary force behind Made-in-India SSI Mantra Surgical Robotic System, has achieved a historic feat in Indian medical science by becoming the first and only company in India to receive Central Drugs Standard Control Organization (CDSCO) regulatory approval for Telesurgery and Teleproctoring, signifying a monumental leap in surgical robotics.
This landmark achievement positions SSI Mantra as the first surgical robotic system in India authorised to perform these advanced capabilities. It paves the way for SS Innovations' commitment to advancing surgical technology, making cutting-edge procedures more accessible, and reinforcing the position of India as a global leader in healthcare innovation.
Telesurgery, first envisioned in the 1980s for use in space and on remote battlefields, faced significant challenges due to the technological limitations and lack of bandwidth available at the time. Today, with advancements in both technology and connectivity, SSI has turned this vision into reality with its groundbreaking SSI Mantra Surgical Robotic System.
By enabling Telesurgery and Teleproctoring, the system aims to decentralise and democratise access to surgical expertise, addressing critical gaps in healthcare, particularly in remote areas, where access to specialized medical care has often been a challenge.
This historic achievement marks a significant step forward in India’s healthcare landscape, with SSI leading the charge in revolutionising surgical care through cutting-edge technology. The approval of Telesurgery and Teleproctoring capabilities for SSI Mantra Surgical Robotic Systems not only underscores the company’s commitment to innovation but also opens up new possibilities for accessible, high-quality healthcare across India and beyond.
